26 Dec, EOD - Indian

SENSEX 78472.48 (0.00)

Nifty 50 23750.2 (0.10)

Nifty Bank 51170.7 (-0.12)

Nifty IT 43664.25 (-0.01)

Nifty Midcap 100 57125.7 (0.12)

Nifty Next 50 69165.85 (0.45)

Nifty Pharma 22712.55 (0.68)

Nifty Smallcap 100 18728.65 (-0.02)

26 Dec, EOD - Global

NIKKEI 225 39568.06 (1.12)

HANG SENG 20098.29 (1.08)

S&P 6105 (-0.04)

LOGIN HERE

Alembic Pharmaceuticals Ltd

You are Here : Home > Markets > CompanyInformation > Company Background
BSE Code : 533573 | NSE Symbol : APLLTD | ISIN : INE901L01018 | Industry : Pharmaceuticals |


Chairman's Speech

‘OUR LEADERSHIP TEAM IS LEAVING NO STONE UNTURNED TO ENSURE THAT ALEMBIC ALWAYS REMAINS AT THE CUTTING EDGE OF TECHNOLOGY AND CONTINUES TO FOSTER A CULTURE OF INNOVATION. THE POTENT COMBINATION OF KNOWLEDGE AND TECHNOLOGY WILL ALLOW US TO STAY AHEAD OF THE SECTORAL CURVE'.

Dear Shareholders,

I am privileged to present the Annual Report for the fiscal 2023-24. Your Company has progressed well and is poised to significantly contribute to a healthier world through its affordable and innovative medicines.

Our efforts towards positioning Alembic as a multi-disciplinary, multi-capability pharmaceutical company have taken shape and are reflected in our improved all-around performance. While a lot has been done to position Alembic as a global pharmaceutical organisation, much more needs to be done, considering the tectonic trends expected to emerge in the current decade.

TRENDS IN THE GLOBAL HEALTHCARE INDUSTRY

At the macro level, the healthcare industry will experience considerable demographic changes that will impact service delivery models and even the kind of services needed.

1) A longer-living population, the emergence of transformative technologies with applications across the healthcare spectrum and continued global economic uncertainties are vital societal drivers that will impact the global healthcare space over the coming years.

2) With Millennials, Generation X and Baby Boomers entering their new stages in life all at the same time, there will be a growing demand for affordable but quality and convenient care, along with more efficient management of chronic illnesses.

3) Extreme weather events could become the biggest global risk over the next decade. Global health is one of the main areas where this will be felt. Credible sources suggest that by 2050, the climate crisis could cause economic losses worth US$12.5 trillion and add US$1.1 trillion in extra costs to healthcare systems around the globe. At the micro level, certain critical ailments will take centre stage. Cancer is a case in point. Cancer is on the rise worldwide. This appears to be due to lifestyle changes, increased consumption of certain processed foods that have not been subjected to proper quality control tests, pollution, genetic predispositions, and increased awareness and diagnostic advancements. Recent research has unearthed that global cases of early-onset cancer have increased. There were close to 20 million new cases of cancer in the year 2022, and the numbers continue to rise rapidly. In other words, cancer is fast becoming an epidemic.

THE FUTURE OF THE INDIAN PHARMA SECTOR

India, the pharmacy of the world, is experiencing a compelling growth trajectory with high single-digit growth. Despite challenges in CIS countries, the global reception of Indian pharmaceuticals remains positive. Moreover, the domestic market has exhibited a healthy double-digit growth. These realities position the domestic industry firmly on the path to reach the US$130 billion mark by 2030.

INDIAN HEALTHCARE _ AN IRREVERSIBLE CHANGE

Indian healthcare is undergoing a transformative phase - an irreversible change in healthcare consumption, with patients and doctors increasingly embracing technology for healthcare interactions. This change is largely attributed to the rapid advancements made by health tech companies. Interestingly, these disruptions have unlocked new value pools within the sector.

The digital transformation of India's healthcare industry has the potential to accelerate tenfold, from US$2.7 billion in 2022 to approximately US$37 billion by 2030.1 This will rub off into a stronger demand for pharmaceutical products.

OUR PREPAREDNESS FOR A BETTER TOMORROW

We are present across the world and closely connected with a large section of opinion influencers and decision-makers in the global and domestic pharmaceutical markets. These connections provide rich insights into how our business space is evolving at the macro level and in every nation we operate.

The knowledge helps us prepare proactively for the fast-evolving healthcare world. Our teams are working round-the-clock to develop products and platforms that will address the needs of a more evolved and tech-savvy society of tomorrow. This will increase our relevance in an increasingly competitive business space.

Our leadership team is leaving no stone unturned to ensure that Alembic always remains at the cutting edge of technology and continues to foster a culture of innovation. The potent combination of knowledge and technology will allow us to stay ahead of the sectoral curve and unleash value for all those who stay aligned with our story.

In closing, let me emphasise how grateful I am for all your support. This has been the greatest source of my strength, and I promise I will do my utmost to uphold your trust in me and my team.

Regards

CHIRAYU AMIN

Chairman & CEO